Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 EUR | +1.67% | -3.84% | +79.37% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 177
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Single Pills - Hypertension
69.4
%
| 37 | 65.6 % | 26 | 69.4 % | -29.84% |
Co-Marketing - CO PD (Respiratory Diseases)
21.5
%
| 10 | 17.9 % | 8 | 21.5 % | -20.21% |
Corporate Brands (without Single Pills) - Other
5.6
%
| 2 | 3.8 % | 2 | 5.6 % | -3.07% |
Co-Marketing - Cardiovascular
3.1
%
| - | - | 1 | 3.1 % | - |
Co-Marketing - Diabetes
0.5
%
| 7 | 12.3 % | 0 | 0.5 % | -97.44% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Germany
100.0
%
| 56 | 100.0 % | 37 | 100.0 % | -33.67% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sven Pauly
IRC | Investor Relations Contact | - | - |
Sanjeev Gotru
PRN | Corporate Officer/Principal | - | - |
Susanne Endreß
LAW | General Counsel | - | - |
Harald Weyand
SAM | Sales & Marketing | - | - |
Matthias Wendl
SAM | Sales & Marketing | - | - |
Thomas Milz
PRN | Corporate Officer/Principal | 59 | 20-12-31 |
Susanne Böhme
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
Chairman | 51 | 20-12-31 | |
Director/Board Member | 39 | 20-12-31 | |
Director/Board Member | - | 22-04-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 8,500,000 | 8,330,000 ( 98.00 %) | 170,000 ( 2.000 %) | 98.00 % |
Company contact information
APONTIS PHARMA AG
Alfred-Nobel-Strasse 10
40789, Monheim am Rhein
+49 2173 8955 4949
https://www.apontis-pharma.deSector
Sales per Business
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+79.37% | 75.69M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- APPH Stock
- Company Apontis Pharma AG